Redeye provides an update on ChromoGenics following the company's Q3 2023 results. New cooperations with strong order intatake signalls a potential turnaround. We estimate sales to double next year.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases